Featured news from NHIVNA
HIV-related news from NAM
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
Liz Highleyman, 2015-05-11 07:20:00
Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of genotype 1 chronic hepatitis C patients with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
The sustained response rate in HCV-TARGET fell to 39% for genotype 3, but another study found that 70% of genotype 3 patients with decompensated cirrhosis could be cured with sofosbuvir plus daclatasvir (Daklinza), while sofosbuvir/ledipasvir (Harvoni) cured up to 86% of genotype 1 patients.
Interferon-free regimens of direct-acting antiviral agents (DAAs) can now cure most chronic hepatitis C patients including those traditionally considered difficult to treat. But challenges remain when treating people with the most advanced liver disease - a population that has trouble tolerating and responds poorly to interferon-based therapy.
Source:1
